Evidence map›Paper›PMID 38858380›Full record

SynthesisTranslational psychiatry2024

Hippocampal transcriptome-wide association study and pathway analysis of mitochondrial solute carriers in Alzheimer's disease.

Jing Tian, Kun Jia, Tienju Wang, Lan Guo, Zhenyu Xuan, Elias K Michaelis, Russell H Swerdlow, Alzheimer’s Disease Neuroimaging Initiative, Heng Du

Abstract readMeta-Analysis
In one paragraph

Synthesis in Translational psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jing Tian *Department of Pharmacology and Toxicology, University of Kansas, Lawrence, KS, USA.
Kun Jia *Department of Pharmacology and Toxicology, University of Kansas, Lawrence, KS, USA.
Tienju WangDepartment of Pharmacology and Toxicology, University of Kansas, Lawrence, KS, USA.
Lan GuoDepartment of Pharmacology and Toxicology, University of Kansas, Lawrence, KS, USA.
Zhenyu XuanDepartment of Biological Sciences, The University of Texas at Dallas, Richardson, TX, USA.
Elias K MichaelisDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA.
Russell H SwerdlowAlzheimer's Disease Research Center, University of Kansas Medical Center, Kansas City, KS, USA.ORCID 0000-0003-2948-7230
Alzheimer’s Disease Neuroimaging Initiative
Heng DuDepartment of Pharmacology and Toxicology, University of Kansas, Lawrence, KS, USA. heng.du@ku.edu.ORCID 0000-0002-2661-5818

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Duygu Tosun-Turgut · 2016 to 2026
$226.7M
University of Kansas Alzheimer's Disease Research Center (KU ADRC)P30AG072973 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI JEFFREY Murray BURNS, RUSSELL H. SWERDLOW · 2021 to 2026
$25.3M
University of Kansas Alzheimer's Disease Core CentersP30AG035982 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI SWERDLOW, RUSSELL H. · 2011 to 2020
$16.6M
GOAT-mediated ghrelin deregulation and hippocampal pathology in Alzheimer's DiseaseR01AG059753 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Heng Du · 2018 to 2026
$3.4M
mtDNA leakage and STING-dependent microglial innate immune response in Alzheimer's diseaseR01AG075108 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Heng Du · 2022 to 2026
$2.4M
Mitochondrial ATP Synthase Dysfunction and Synaptic Stress in Alzheimer's DiseaseR01AG053588 · NIA · UNIVERSITY OF TEXAS DALLAS · PI DU, HENG · 2016 to 2020
$1.9M
BrightFocus Foundation (BrightFocus) A20201159SBrightFocus Foundation (BrightFocus) A2022036SFoundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01AG059753Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01AG075108NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG072973NIA NIH HHS R01 AG053588NIA NIH HHS R01 AG059753NIA NIH HHS R01 AG075108NIA NIH HHS U19 AG024904University of Kansas (Kansas University) 2302009
6 · The paper itself

Abstract

The etiopathogenesis of late-onset Alzheimer's disease (AD) is increasingly recognized as the result of the combination of the aging process, toxic proteins, brain dysmetabolism, and genetic risks. Although the role of mitochondrial dysfunction in the pathogenesis of AD has been well-appreciated, the interaction between mitochondrial function and genetic variability in promoting dementia is still poorly understood. In this study, by tissue-specific transcriptome-wide association study (TWAS) and further meta-analysis, we examined the genetic association between mitochondrial solute carrier family (SLC25) genes and AD in three independent cohorts and identified three AD-susceptibility genes, including SLC25A10, SLC25A17, and SLC25A22. Integrative analysis using neuroimaging data and hippocampal TWAS-predicted gene expression of the three susceptibility genes showed an inverse correlation of SLC25A22 with hippocampal atrophy rate in AD patients, which outweighed the impacts of sex, age, and apolipoprotein E4 (ApoE4). Furthermore, SLC25A22 downregulation demonstrated an association with AD onset, as compared with the other two transcriptome-wide significant genes. Pathway and network analysis related hippocampal SLC25A22 downregulation to defects in neuronal function and development, echoing the enrichment of SLC25A22 expression in human glutamatergic neurons. The most parsimonious interpretation of the results is that we have identified AD-susceptibility genes in the SLC25 family through the prediction of hippocampal gene expression. Moreover, our findings mechanistically yield insight into the mitochondrial cascade hypothesis of AD and pave the way for the future development of diagnostic tools for the early prevention of AD from a perspective of precision medicine by targeting the mitochondria-related genes.

Indexed as

Alzheimer DiseaseHippocampusTranscriptomeAgedAged, 80 and overAtrophyFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMaleMitochondriaMitochondrial Membrane Transport ProteinsMitochondrial Membrane Transport Proteins

Identifiers

PMID38858380
PMCPMC11164935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.